Tables of Rules

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

Attachment inhibitor Integrase strand transfer inhibitors

HIV - 2    

  Mutations associated with resistance Mutations associated with « possible resistance »
EFV
L100I
K101E
K103H/N/S/T [1]
V106M [2]
E138K [12, 13]
Y181C/I
Y188C/L
G190A/C/E/Q/S/T/V
P225H
M230L

NVP
A98S (for HIV-1 subtype C only) [3]
L100I
K101E
K103H/N/S/T [1]
V106A/M [2]
Y181C/I
Y188C/H/L
G190A/C/E/Q/S/T/V
M230L
E138K [13]

ETR

At least 3 among: V90I, A98G, L100I, K101E/H/I/P/R, V106I, V179D/F/I/L/M/T, G190A/S, M230L [4, 7, 8, 9, 10, 11]
E138K [12, 13]
Y181C/I/V [5, 6]
H221Y [12,16]
2 mutations among: V90I, A98G, L100I, K101E/H/I/P/R, V106I, V179D/F/I/L/M/T, G190A/S, M230L [4, 7, 8, 9, 10, 11]
E138A/G/Q/R/S [5, 6, 7, 8]
RPV K101E/P [9, 13]
E138A/G/K/Q/R/S [12, 13, 14]
V179L [9]
Y181C/I/V [13]
Y188L [9]
F227C [9]
H221Y [13]
M230I/L/V [9]
L100I + K103N/S [9, 15]
L100I + K103R + V179D [15]
A98G [22]
DOR

V106A/M [17, 18, 19, 20, 21]
Y188L
G190E/S [21]
M230L
L100I + K103N [17, 19]
K103N + Y181C
K103N + P225H
F227C [21]
At least 4 among: A98G, L100I, K101E, V106I, E138K, Y181C/V, G190A or H221Y [23]

At least 2 among: A98G, L100I, K101E, V106I, E138K, Y181C/V, G190A or H221Y [23]

EFV: efavirenz, NVP: nevirapine, ETR: etravirine, RPV : rilpivirine, DOR : doravirine.

For DNA provirus, impact of stop codons and G->A mutations on ARV resistance is unknown.

References